IRADIMED CORPORATION (IRMD) Financial Statements
IRADIMED CORPORATION (IRMD) reported trailing twelve-month revenue of $86.3M (up 11.2% year on year) and net income of $23.1M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $24.5M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IRMDIRADIMED CORPORATIONFollow IRMD — free
—
Price chart with a free account
- Market cap
- 1.1B
- P/E TTM
- 47.9
- Dividend yield
- 0.9%
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.7 | 31.6 | 32.5 | 23.1 | 30.4 | 38.5 | 31.7 | 41.8 | 53.3 | 65.6 | 73.2 | 83.8 | 86.3 | |
| Gross profit | 12.2 | 25.8 | 26.3 | 17.5 | 23.2 | 29.7 | 23.6 | 32.0 | 41.3 | 50.2 | 56.4 | 64.3 | 65.5 | |
| Research & development | 1.1 | 1.8 | 1.3 | 1.7 | 1.5 | 1.4 | 1.9 | 1.9 | 2.3 | 2.9 | 2.8 | 3.0 | 3.1 | |
| Operating income | 3.1 | 11.5 | 10.9 | 1.3 | 6.0 | 8.6 | -0.8 | 9.8 | 15.6 | 20.0 | 22.0 | 26.1 | 27.6 | |
| Pre-tax income | 3.0 | 11.6 | 11.0 | 1.4 | 6.2 | 9.0 | -0.6 | 9.8 | 16.2 | 21.7 | 24.3 | 28.4 | 29.7 | |
| Income tax | 1.0 | 4.1 | 3.7 | 0.9 | -0.1 | -0.6 | -2.0 | 0.5 | 3.4 | 4.5 | 5.0 | 5.9 | 6.7 | |
| Net income | 2.1 | 7.5 | 7.2 | 0.5 | 6.3 | 9.6 | 1.4 | 9.3 | 12.8 | 17.2 | 19.2 | 22.5 | 23.1 | |
| Diluted EPS ($) | 0.20 | 0.60 | 0.60 | 0.04 | 0.52 | 0.78 | 0.11 | 0.74 | 1.02 | 1.35 | 1.50 | 1.75 | 1.79 | |
| Diluted shares (mn) | 10.2 | 12.6 | 12.0 | 11.7 | 12.1 | 12.3 | 12.4 | 12.6 | 12.6 | 12.7 | 12.8 | 12.9 | — |
USD millions · SEC XBRL
IRADIMED CORPORATION — questions
- What is IRADIMED CORPORATION's revenue?
- $86.3M over the twelve months to 2026-06-30, up 11.2% year on year, from its 10-Q and 10-K filings.
- What is IRADIMED CORPORATION's net income?
- $23.1M over the twelve months to 2026-06-30.
- What is IRADIMED CORPORATION's free cash flow?
- $24.5M over the twelve months to 2026-06-30.
- What are IRADIMED CORPORATION's diluted earnings per share?
- $1.79 over the twelve months to 2026-06-30.
Every figure on this page comes from IRADIMED CORPORATION's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.